Angiotensin receptor blockers use and the risk of lung cancer: A meta-analysis

作者：Zhang, Weizhen; Liang, Zhenyu; Li, Jing; Cai, Shaoxi^*

来源：Journal of the Renin-Angiotensin-Aldosterone System, 2015, 16(4): 768-773.

DOI：10.1177/1470320315607391

• Angiotensin receptor blocker
• lung cancer
• association
• meta-analysis

Background: Several reports suggest that the use of angiotensin receptor blockers (ARBs) is associated with lung cancer (LC) reduction. However, the results were contradictory. @@@ Methods: Four online databases were searched. The strength of the association between ARB and the risk of LC was measured by odds ratio (OR) and 95% confidence interval (CI). OR was analyzed by random-effects model. @@@ Results: Eight studies with 298000 subjects were included in this meta-analysis. Using of ARB was significantly associated with decreased LC risk (OR = 0.81; 95% CI 0.69-0.94; p = 0.005). In the subgroup analysis by race, Asians treated with ARB showed decreased LC risk (OR = 0.60; 95% CI 0.54-0.67; p < 0.00001). However, Caucasians treated with ARB did not show significantly decreased LC risk (OR = 0.90; 95% CI 0.79-1.02; p = 0.11). Subgroup analysis by duration of follow-up was conducted. The studies with less than 5 years showed significant result (OR = 0.79; 95% CI 0.64-0.97;p = 0.02). However, the studies with more than 5 years did not show significantly decreased LC risk (OR = 0.84; 95% CI 0.61-1.16; p = 0.29). @@@ Conclusions: This meta-analysis indicated that ARBs may be associated with decreased risk of LC.

• 出版日期2015-12
• 单位南方医科大学